Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Botulinum toxin drugs: future developments.

D Dressler1

  • 1Department of Neurology, Rostock University, Rostock, Germany. dirk.dressler@med.uni-rostock.de

Journal of Neural Transmission (Vienna, Austria : 1996)
|March 26, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

New formulation of Botox: complete antibody-induced treatment failure in cervical dystonia.

BMJ case reports·2025
Same author

Association of Motor and Cognitive Symptoms with Health-Related Quality of Life and Caregiver Burden in a German Cohort of Advanced Parkinson's Disease Patients.

Parkinson's disease·2020
Same author

Caregiver burden and health-related quality of life in idiopathic dystonia patients under botulinum toxin treatment: a cross-sectional study.

Journal of neural transmission (Vienna, Austria : 1996)·2019
Same author

Validating the Parkinson's disease caregiver burden questionnaire (PDCB) in German caregivers of advanced Parkinson's disease patients.

International psychogeriatrics·2019
Same author

[Treatment goals in patients with post-stroke upper limb spasticity following injection of botulinum toxin A : Results of the German-Austrian subgroup of the ULIS-II study].

Der Nervenarzt·2018
Same author

Impaired heart rate variability in cervical dystonia is associated to depression.

Journal of neural transmission (Vienna, Austria : 1996)·2016
Same journal

Stress and resilience: cortisol hypo-response to acute stress in non-resilient individuals.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same journal

Dopamine supersensitivity psychosis: a critical evaluation of diagnostic validators.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same journal

A refined protocol for the large-scale production of high-quality cerebral organoids.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same journal

Investigating smiling asymmetries in Parkinson's disease through the whistle-smile reflex.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same journal

The German Parkinson expert meetings.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same journal

Changes in leukocytes and CRP in different treatments of major depression.

Journal of neural transmission (Vienna, Austria : 1996)·2026
See all related articles

Botulinum toxin (BoNT) drugs are safe and effective, with over $1 billion in annual sales. Ongoing research aims to improve BoNT therapies through enhanced antigenicity, new delivery methods, and better stability for continued success.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Drug Development

Background:

  • Botulinum toxin (BoNT) drugs have achieved significant clinical success for over two decades.
  • The global market for BoNT therapies exceeds one billion US dollars annually.
  • Despite widespread use, BoNT drug development is ongoing.

Purpose of the Study:

  • To outline the future directions and ongoing innovations in Botulinum toxin (BoNT) drug development.
  • To highlight key areas for improvement in BoNT product characteristics and applications.
  • To emphasize the continuous need for advancement in BoNT therapies.

Main Methods:

  • Focus on enhancing antigenicity through increased biological activity and protein separation.
  • Exploration of high-affinity BoNT variants and shielding of antigenic epitopes.

Related Experiment Videos

  • Development of novel applications such as transdermal delivery and imaging-guided use.
  • Improvement of drug formulation, including ready-made solutions and enhanced stability.

    • Main Results:

    • New BoNT drug formulations are emerging with improved features.
    • Specific advancements include better antigenicity, novel delivery systems, and enhanced stability.
    • The development pipeline addresses key limitations of current BoNT therapies.

    Conclusions:

    • Botulinum toxin (BoNT) drugs represent a safe and effective therapeutic class.
    • Continuous research and development are crucial for optimizing BoNT therapies.
    • Future innovations will likely focus on improved efficacy, targeted delivery, and extended shelf-life.